[Introduction of genetic analysis can provide us with safer doping tests. Large variation in androgen turnover creates problems in current tests].
Avdelningen för klinisk farmakologi, institutionen för laboratoriemedicin, Karolinska institutet, Karolinska universitetssjukhuset, Huddinge. anders.rane@ki.se
Anders
A
Rane
Lena
L
Ekström
D000728:Androgens / Q000235:genetics / Q000378:metabolism*; D054708:Cyclic Nucleotide Phosphodiesterases, Type 7 / Q000235:genetics / Q000378:metabolism; D004300:Doping in Sports / Q000208:ethnology; D004845:Epitestosterone / Q000235:genetics / Q000378:metabolism / Q000652:urine; D005838:Genotype; D060005:Genotyping Techniques; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D015778:Minor Histocompatibility Antigens; D012680:Sensitivity and Specificity; D013254:Steroid 17-alpha-Hydroxylase / Q000235:genetics / Q000378:metabolism; D013739:Testosterone / Q000235:genetics / Q000378:metabolism* / Q000652:urine
D000728:Androgens; D015778:Minor Histocompatibility Antigens; D013739:Testosterone; D004845:Epitestosterone; D013254:Steroid 17-alpha-Hydroxylase; D014453:Glucuronosyltransferase; C500513:UGT2B17 protein, human; D054708:Cyclic Nucleotide Phosphodiesterases, Type 7; C517463:PDE7B protein, human